Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Table 1

Characteristic comparison of MM patients with or without ASCT in three risk subgroups.

	High risk			Intermediate risk			Low risk
	Non-ASCT	ASCT		Non-ASCT	ASCT		Non-ASCT	ASCT
Number	17	17		24	24		26	26
Average age (years)	56.0	52.0	0.154	54.0	51.4	0.288	53.5	53.0	0.820
Male/female	11/6	9/8	0.486	16/8	16/8	1.000	18/8	14/12	0.254
IgA class	29.40%	23.50%	1.000	25.00%	20.80%	0.731	19.20%	19.20%	1.000
Average hemoglobin (g/L)	85.5	72.4	0.169	76.9	77.7	0.948	110.4	95.7	0.136
Average serum calcium (mmol/L)	2.69	2.38	0.143	2.62	2.80	0.356	2.44	2.42	0.899
Average creatinine (umol/L)	136.8	188.3	0.456	224.3	160.0	0.493	74.0	90.8	0.189
Average albumin (g/L)	32.5	31.4	0.728	34.7	38.9	0.133	36.5	36.0	0.891
Average 2 microglobulin (mg/L)	6.02	6.25	0.884	8.27	6.54	0.374	3.04	3.54	0.33
Median bone marrow plasma cells	49.2%	46.2%	0.803	7.6%	13.8%	0.441	28.8%	35.3%	0.382
nCR/CR rate	41.20%	47.10%	0.730	29.20%	37.50%	0.540	42.30%	50.00%	0.578